Pfizer Shares Rise to $27.79 with Active Options Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PFE?
Moderately bullish activity in Pfizer (PFE), with shares up 22c, or 0.82%, near $27.79. Options volume roughly in line with average with 70k contracts traded and calls leading puts for a put/call ratio of 0.4, compared to a typical level near 0.55. Implied volatility (IV30) is higher by 0.6 points near 26.24,and above the 52wk median, suggesting an expected daily move of $0.46. Put-call skew steepened, indicating increased demand for downside protection.Looking ahead: Pfizer (PFE) will report earnings after the close on None.Option markets are pricing in a 50% probability of a move greater than 0.0% or $0.00.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.670
Low
24.00
Averages
28.56
High
35.00
Current: 26.670
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb-Pfizer Alliance Partners with Cost Plus Drugs for Eliquis Access
- Expanded Access Channels: The Bristol Myers Squibb-Pfizer Alliance has partnered with Cost Plus Drugs to offer Eliquis on CostPlusDrugs.com starting April 27, 2026, allowing cash-paying patients to purchase the medication for $345, significantly lowering access costs and enhancing patient availability.
- Market Demand Response: This collaboration addresses the strong market demand for Eliquis, with Cost Plus Drugs co-founder Mark Cuban emphasizing that patients should not have to guess medication prices, thereby providing a clearer and more direct access route that empowers patients.
- Healthcare Cost Savings: Eliquis is projected to save an estimated $3 billion in healthcare costs for every 100,000 patients treated, reducing hospitalization and rehabilitation needs, highlighting the drug's strategic importance in improving patient health and lowering overall healthcare expenditures.
- Continuation of Patient Support Programs: This partnership follows the 2025 launch of the Eliquis 360 Support program, further solidifying the BMS-Pfizer Alliance's commitment to patient resource support and aiming to enhance patient medication experiences through diversified access channels.
See More
CDC Blocks Publication of COVID Vaccine Study Despite Review
- Publication Blocked: The CDC has blocked the publication of a report on COVID-19 vaccines reducing hospitalization risk after it passed scientific review, a highly unusual action that indicates internal sensitivity regarding vaccine efficacy research.
- Methodology Controversy: HHS spokesperson noted that CDC leadership routinely flags concerns about MMWR papers, particularly regarding methodology, and the current study's observational method has raised doubts, potentially undermining public trust in vaccines.
- Vaccine Effectiveness Comparison: While the COVID vaccine study is on hold, a flu vaccine effectiveness study using the same methodology was published in March, highlighting inconsistencies in CDC's handling of vaccine research that may raise public skepticism about vaccine policies.
- Policy Changes Impact: Under HHS Secretary RFK Jr., the CDC has removed vaccine recommendations for healthy children and pregnant women and paused federal funding for mRNA vaccine research, a series of policy shifts that could affect vaccination rates and public health strategies.
See More
AbbVie vs. Pfizer: A Financial Comparison
- Patent Management Advantage: AbbVie has effectively managed its patent portfolio with 130 patents surrounding its immunology therapy Humira, which was the world's best-selling drug for six consecutive years, while Pfizer's Comirnaty took the lead during the pandemic, AbbVie's drug lineup shows greater market resilience.
- Sales Growth Potential: AbbVie's Skyrizi and Rinvoq are projected to generate $17.6 billion and $8.3 billion in sales in 2025, respectively, totaling $25.9 billion, which significantly surpasses Humira's $21.2 billion in 2022, highlighting the diversification and profitability of its product portfolio.
- Dividend Safety: While Pfizer boasts a dividend yield of 6.3%, its payout ratio of 107% indicates unsustainability, whereas AbbVie offers a 3.2% yield with a more manageable payout ratio of 65%, suggesting a more stable dividend payment structure.
- Financial Growth Outlook: AbbVie expects to achieve revenue of around $67 billion in 2026, reflecting a 9.5% increase, while Pfizer's revenue is projected to decline by 2.5%, showcasing AbbVie's clear advantage in financial growth prospects.
See More
EXCLUSIVE: SOURCES REVEAL MERCK AND COMPETITORS SHOWING INTEREST IN INHIBRX'S EXPERIMENTAL CANCER TREATMENT LINKED TO KEYTRUDA
Interest in InhibRx: Merck and other rivals are showing interest in InhibRx, a company involved in experimental cancer drug development.
Key Drug Tied to Trudeau: The experimental cancer drug being discussed is reportedly linked to key figures, including Canadian Prime Minister Justin Trudeau.
See More
Pfizer's Xianweiying Weight Management Treatment Available for Pre-Order in China
- Increased Market Competition: Pfizer's GLP-1 weight management treatment Xianweiying is now available for pre-order in China, intensifying competition with rivals like Novo Nordisk and Eli Lilly in a market analysts project to be worth billions of dollars.
- Pricing and Shipping: A 1.2 ml Xianweiying injector pen is priced at 489 yuan ($72) according to JD.com, with shipping set to begin on April 27, a pricing strategy that could influence consumer choices and reshape market dynamics.
- Sales Data Comparison: Jefferies reports that Novo's Wegovy generated sales of 260 million yuan ($38 million) in 2025, while Innovent's Xinermei achieved 416 million yuan ($61 million), highlighting the substantial market potential for weight-loss drugs.
- Strategic Acquisitions and Licensing: Pfizer licensed the commercialization rights for Xianweiying in mainland China in February and has acquired obesity drug developer Metsera, further solidifying its position in the rapidly growing weight-loss drug market.
See More
Pfizer Unveils New Therapy Data at ASCO Meeting
- New Therapy Evidence: Pfizer presented new evidence for LORBRENA® and BRAFTOVI® at the ASCO meeting, reinforcing their status as standard treatments for ALK-positive non-small cell lung cancer and BRAF-mutant colorectal cancer, which is expected to significantly improve patient survival rates and quality of life.
- Early Treatment Potential: The clinical trial of TALZENNA® plus XTANDI® in metastatic castration-sensitive prostate cancer showed significant improvements in radiographic progression-free survival (rPFS), indicating that early intervention may yield better treatment outcomes and enhancing Pfizer's competitive position in the prostate cancer market.
- Pipeline Advancement: Updates on novel mechanisms such as PF-08634404 and sigvotatug vedotin across various solid tumors demonstrate their potential applications in different cancer types, potentially providing more treatment options for the future and further solidifying Pfizer's leadership in oncology.
- Clinical Research Findings: Pfizer will share data from over 40 research abstracts at ASCO, including three late-breaking presentations and eight oral presentations, emphasizing its ongoing innovation in cancer treatment and commitment to patients, which is expected to drive future growth and market share enhancement.
See More
Bristol Myers Squibb-Pfizer Alliance Partners with Cost Plus Drugs for Eliquis Access
- Expanded Access Channels: The Bristol Myers Squibb-Pfizer Alliance has partnered with Cost Plus Drugs to offer Eliquis on CostPlusDrugs.com starting April 27, 2026, allowing cash-paying patients to purchase the medication for $345, significantly lowering access costs and enhancing patient availability.
- Market Demand Response: This collaboration addresses the strong market demand for Eliquis, with Cost Plus Drugs co-founder Mark Cuban emphasizing that patients should not have to guess medication prices, thereby providing a clearer and more direct access route that empowers patients.
- Healthcare Cost Savings: Eliquis is projected to save an estimated $3 billion in healthcare costs for every 100,000 patients treated, reducing hospitalization and rehabilitation needs, highlighting the drug's strategic importance in improving patient health and lowering overall healthcare expenditures.
- Continuation of Patient Support Programs: This partnership follows the 2025 launch of the Eliquis 360 Support program, further solidifying the BMS-Pfizer Alliance's commitment to patient resource support and aiming to enhance patient medication experiences through diversified access channels.
See More
CDC Blocks Publication of COVID Vaccine Study Despite Review
- Publication Blocked: The CDC has blocked the publication of a report on COVID-19 vaccines reducing hospitalization risk after it passed scientific review, a highly unusual action that indicates internal sensitivity regarding vaccine efficacy research.
- Methodology Controversy: HHS spokesperson noted that CDC leadership routinely flags concerns about MMWR papers, particularly regarding methodology, and the current study's observational method has raised doubts, potentially undermining public trust in vaccines.
- Vaccine Effectiveness Comparison: While the COVID vaccine study is on hold, a flu vaccine effectiveness study using the same methodology was published in March, highlighting inconsistencies in CDC's handling of vaccine research that may raise public skepticism about vaccine policies.
- Policy Changes Impact: Under HHS Secretary RFK Jr., the CDC has removed vaccine recommendations for healthy children and pregnant women and paused federal funding for mRNA vaccine research, a series of policy shifts that could affect vaccination rates and public health strategies.
See More
AbbVie vs. Pfizer: A Financial Comparison
- Patent Management Advantage: AbbVie has effectively managed its patent portfolio with 130 patents surrounding its immunology therapy Humira, which was the world's best-selling drug for six consecutive years, while Pfizer's Comirnaty took the lead during the pandemic, AbbVie's drug lineup shows greater market resilience.
- Sales Growth Potential: AbbVie's Skyrizi and Rinvoq are projected to generate $17.6 billion and $8.3 billion in sales in 2025, respectively, totaling $25.9 billion, which significantly surpasses Humira's $21.2 billion in 2022, highlighting the diversification and profitability of its product portfolio.
- Dividend Safety: While Pfizer boasts a dividend yield of 6.3%, its payout ratio of 107% indicates unsustainability, whereas AbbVie offers a 3.2% yield with a more manageable payout ratio of 65%, suggesting a more stable dividend payment structure.
- Financial Growth Outlook: AbbVie expects to achieve revenue of around $67 billion in 2026, reflecting a 9.5% increase, while Pfizer's revenue is projected to decline by 2.5%, showcasing AbbVie's clear advantage in financial growth prospects.
See More
EXCLUSIVE: SOURCES REVEAL MERCK AND COMPETITORS SHOWING INTEREST IN INHIBRX'S EXPERIMENTAL CANCER TREATMENT LINKED TO KEYTRUDA
Interest in InhibRx: Merck and other rivals are showing interest in InhibRx, a company involved in experimental cancer drug development.
Key Drug Tied to Trudeau: The experimental cancer drug being discussed is reportedly linked to key figures, including Canadian Prime Minister Justin Trudeau.
See More
Pfizer's Xianweiying Weight Management Treatment Available for Pre-Order in China
- Increased Market Competition: Pfizer's GLP-1 weight management treatment Xianweiying is now available for pre-order in China, intensifying competition with rivals like Novo Nordisk and Eli Lilly in a market analysts project to be worth billions of dollars.
- Pricing and Shipping: A 1.2 ml Xianweiying injector pen is priced at 489 yuan ($72) according to JD.com, with shipping set to begin on April 27, a pricing strategy that could influence consumer choices and reshape market dynamics.
- Sales Data Comparison: Jefferies reports that Novo's Wegovy generated sales of 260 million yuan ($38 million) in 2025, while Innovent's Xinermei achieved 416 million yuan ($61 million), highlighting the substantial market potential for weight-loss drugs.
- Strategic Acquisitions and Licensing: Pfizer licensed the commercialization rights for Xianweiying in mainland China in February and has acquired obesity drug developer Metsera, further solidifying its position in the rapidly growing weight-loss drug market.
See More
Pfizer Unveils New Therapy Data at ASCO Meeting
- New Therapy Evidence: Pfizer presented new evidence for LORBRENA® and BRAFTOVI® at the ASCO meeting, reinforcing their status as standard treatments for ALK-positive non-small cell lung cancer and BRAF-mutant colorectal cancer, which is expected to significantly improve patient survival rates and quality of life.
- Early Treatment Potential: The clinical trial of TALZENNA® plus XTANDI® in metastatic castration-sensitive prostate cancer showed significant improvements in radiographic progression-free survival (rPFS), indicating that early intervention may yield better treatment outcomes and enhancing Pfizer's competitive position in the prostate cancer market.
- Pipeline Advancement: Updates on novel mechanisms such as PF-08634404 and sigvotatug vedotin across various solid tumors demonstrate their potential applications in different cancer types, potentially providing more treatment options for the future and further solidifying Pfizer's leadership in oncology.
- Clinical Research Findings: Pfizer will share data from over 40 research abstracts at ASCO, including three late-breaking presentations and eight oral presentations, emphasizing its ongoing innovation in cancer treatment and commitment to patients, which is expected to drive future growth and market share enhancement.
See More
